Eikon Therapeutics Statistics
Total Valuation
EIKN has a market cap or net worth of $619.89 million. The enterprise value is $278.71 million.
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
EIKN has 54.14 million shares outstanding. The number of shares has increased by 424.44% in one year.
| Current Share Class | 54.14M |
| Shares Outstanding | 54.14M |
| Shares Change (YoY) | +424.44% |
| Shares Change (QoQ) | +1,015.94% |
| Owned by Insiders (%) | 5.89% |
| Owned by Institutions (%) | 37.99% |
| Float | 29.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.13 |
| P/TBV Ratio | 1.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.75, with a Debt / Equity ratio of 0.46.
| Current Ratio | 11.75 |
| Quick Ratio | 11.37 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -394.72 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -41.00% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$890,779 |
| Employee Count | 384 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 10.21 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 63.78 |
| Average Volume (20 Days) | 392,495 |
Short Selling Information
The latest short interest is 4.07 million, so 7.51% of the outstanding shares have been sold short.
| Short Interest | 4.07M |
| Short Previous Month | 3.61M |
| Short % of Shares Out | 7.51% |
| Short % of Float | 13.62% |
| Short Ratio (days to cover) | 11.39 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -330.38M |
| Pretax Income | -338.96M |
| Net Income | -342.06M |
| EBITDA | -310.08M |
| EBIT | -330.38M |
| Earnings Per Share (EPS) | -$32.19 |
Full Income StatementBalance Sheet
The company has $512.18 million in cash and $254.83 million in debt, giving a net cash position of $341.18 million or $6.30 per share.
| Cash & Cash Equivalents | 512.18M |
| Total Debt | 254.83M |
| Net Cash | 341.18M |
| Net Cash Per Share | $6.30 |
| Equity (Book Value) | 550.67M |
| Book Value Per Share | 10.17 |
| Working Capital | 484.44M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$223.80 million and capital expenditures -$24.65 million, giving a free cash flow of -$248.44 million.
| Operating Cash Flow | -223.80M |
| Capital Expenditures | -24.65M |
| Depreciation & Amortization | 20.30M |
| Net Borrowing | n/a |
| Free Cash Flow | -248.44M |
| FCF Per Share | -$4.59 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |